Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pfizer, Washington University Announce Collaboration

Published: Thursday, May 20, 2010
Last Updated: Thursday, May 20, 2010
Bookmark and Share
Pfizer will provide Washington University scientists access to research data on a large array of its pharmaceutical candidates for indications discovery.

In a first-of-a-kind collaboration between academia and industry, Pfizer Inc. will give scientists at Washington University School of Medicine in St. Louis unprecedented access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates in a partnership that focuses on discovering new uses for existing compounds.

Under the five-year agreement, Pfizer will provide $22.5 million to Washington University and give its scientists access to research data on a large array of Pfizer pharmaceutical candidates that are currently or were formerly in clinical testing.

Identifying new uses for existing compounds is known as indications discovery. The potential for its success continues to grow, as scientists understand more fully disease mechanisms at the most basic molecular level and the influence of genetic variations on patients’ responses to medications.

“There are two realities in drug discovery,” explains Don Frail, chief scientific officer of Pfizer’s Indications Discovery Unit. “The majority of candidates tested in development do not give the desired result, yet those drugs that do succeed typically have multiple uses. By harnessing the scientific expertise at this leading academic medical center, the collaboration seeks to discover entirely new uses for these compounds in areas of high patient need that might otherwise be left undiscovered.”

The partnership represents a new approach in academia-industry collaborations that has the potential to develop drug compounds more efficiently. By sharing Pfizer’s data on existing compounds, researchers will not have to replicate extensive preclinical studies, thereby shaving years off the time it takes to evaluate new uses for existing drugs.

The agreement builds on the long history of collaboration between the two organizations and brings together scientists from Pfizer and Washington University to jointly propose, design and carry out research on those compounds across a broad range of disease areas in which the University has internationally renowned scientific expertise, such as Alzheimer’s, cancer, diabetes and related metabolic disorders, and asthma and chronic obstructive pulmonary disease.

“We are pleased to see our long-standing relationship with Pfizer evolve into this innovative model of partnership that has the potential to benefit the many patients whose medical needs can’t be met with existing drugs,” says Larry J. Shapiro, MD, executive vice chancellor and dean of Washington University School of Medicine. “We look forward to the many discoveries that will emerge from this collaboration.”

To encourage the exchange of ideas, Pfizer’s Indications Discovery Unit has developed an online portal through which certain Washington University investigators will have unprecedented access to information about Pfizer’s proprietary compounds, including extensive clinical and preclinical data. The compounds have been extensively studied and their mechanisms of action are well-understood. An advisory committee composed of scientists from both Washington University and Pfizer will evaluate proposals for new research that have been co-written by University and Pfizer researchers.

To facilitate the collaboration, Pfizer’s Indications Discovery Unit is moving its laboratories from Chesterfield, Mo., in suburban St. Louis, to the Center of Research Technology and Entrepreneurial Exchange biosciences district (CORTEX), in the heart of St. Louis’ growing biotech corridor, adjacent to Washington University School of Medicine.

The Washington University-Pfizer partnership has its roots in a research agreement the University signed in 1982 with a St. Louis-based predecessor to Pfizer. The new agreement differs from other relationships in which pharmaceutical companies, even in collaborations with academic scientists, have not disclosed propriety information about drug compounds.

“This is a tremendous opportunity for both partners," says Jeffrey Gordon, MD, director of the University's Center for Genome Sciences, who worked closely with Pfizer on the new agreement. “It leverages the complementary strengths and interests of both Washington University and Pfizer. By creating this innovative new framework, academic and pharmaceutical researchers can collaborate in ways that are mutually advantageous for the University, Pfizer and society to meet the needs of patients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pfizer Inaugurates Center of Excellence in Precision Medicine with Strong Focus on Genomics
Work conducted at center to revolutionize diagnosis and treatment of cancer globally.
Thursday, July 09, 2015
Merck and Pfizer Finalize Agreement to Co-Promote XALKORI®
Co-promotion of XALKORI allows the alliance between Merck KGaA, Darmstadt, Germany, and Pfizer to establish a combined oncology sales organization in key markets for the program.
Thursday, April 09, 2015
Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform
Signs collaboration with Spark Therapeutics to advance phase 1/2 Adeno-associated virus (AAV) vector program in hemophilia B.
Friday, December 12, 2014
Pfizer, Merck to Evaluate Novel Anti-Cancer Combination Regimen
This multi-center, open-label clinical study will be conducted by Pfizer and is expected to begin in 2015.
Wednesday, August 27, 2014
Pfizer Confirms Interest in AstraZeneca
Pfizer submitted a preliminary, non-binding indication of interest to the board of directors of AZ in January 2014 regarding a possible merger transaction.
Monday, April 28, 2014
Pfizer and Samsung Medical Center Collaborate on Liver Cancer
Collaboration aims to conduct joint research to identify genomic mechanisms responsible for clinical outcomes in hepatocellular carcinoma.
Friday, July 16, 2010
Scientific News
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Genes That Increase Children's Risk Of Blood Infection Identified
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!